Explore

Trendline Trendline
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference Highlighting Novel Drug Developments

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference Highlighting Novel Drug Developments

AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference Highlighting Novel Drug Developments
Trendline Trendline
Zai Lab Announces Leadership Change Amid Strategic Shift

Zai Lab Announces Leadership Change Amid Strategic Shift

Zai Lab Announces Leadership Change Amid Strategic Shift
Trendline Trendline
Innate Pharma Concludes 2026 Annual General Meeting with Key Resolutions Passed

Innate Pharma Concludes 2026 Annual General Meeting with Key Resolutions Passed

Innate Pharma Concludes 2026 Annual General Meeting with Key Resolutions Passed
Trendline Trendline
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments
Trendline Trendline
Dr. Eric Green Leads Trace Neuroscience in Biotech Revival

Dr. Eric Green Leads Trace Neuroscience in Biotech Revival

Dr. Eric Green Leads Trace Neuroscience in Biotech Revival
Trendline Trendline
Viking Therapeutics to Present at Major Investor Conferences in June

Viking Therapeutics to Present at Major Investor Conferences in June

Viking Therapeutics to Present at Major Investor Conferences in June
Trendline Trendline
Innate Pharma's 2026 AGM Concludes with All Resolutions Passed

Innate Pharma's 2026 AGM Concludes with All Resolutions Passed

Innate Pharma's 2026 AGM Concludes with All Resolutions Passed
Trendline Trendline
Accent Therapeutics to Present ATX-295 Clinical Study at ASCO 2026, Targeting Advanced Tumors

Accent Therapeutics to Present ATX-295 Clinical Study at ASCO 2026, Targeting Advanced Tumors

Accent Therapeutics to Present ATX-295 Clinical Study at ASCO 2026, Targeting Advanced Tumors
Trendline Trendline
Sarah Cannon Research Institute and Pfizer Collaborate to Accelerate Oncology Drug Development

Sarah Cannon Research Institute and Pfizer Collaborate to Accelerate Oncology Drug Development

Sarah Cannon Research Institute and Pfizer Collaborate to Accelerate Oncology Drug Development
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Portfolio with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Portfolio with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Portfolio with Advanced ADC Technology
Trendline Trendline
Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026

Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026

Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026